how-to-patent-in-china 
Patent Trademark Blog
APRIL 5, 2023
Does it make sense to get a patent in China? One of the most frequent questions I get about getting a patent in China is whether anyone should even bother. Why file a patent overseas when you cannot enforce it? Keep in mind that I am a US patent attorney. Need to file a patent in China?
IP Law 360
MAY 7, 2024
The Seventh Circuit's decision upholding $1 million a day in sanctions against Hytera Communications for violating an order to drop trade secrets and copyright litigation in China highlights the difficulty for lawyers when working alongside Chinese courts, while affirming to patent attorneys how powerful antisuit injunctions can be.
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
LexBlog IP
JANUARY 18, 2024
The BPCIA also introduced a new scheme to resolve patent disputes involving biosimilar products known as the “patent dance.” ” Since the enactment of the BPCIA, the FDA has approved 46 biosimilar products, and, as the market has grown, litigation activity concerning biosimilars has increased rapidly.
LexBlog IP
JULY 19, 2023
New Developments in China Trade Secret Litigation by Founders Legal China’s Growing Focus on Intellectual Property: The Beijing IP Court Steps Up Protections Trade secrets have become increasingly important in today’s globalized business environment, serving as vital intangible assets for many companies.
SpicyIP
APRIL 7, 2024
Significantly, the agreement requires India to make substantive changes to its provision obligating a patent applicant to furnish information about their foreign applications corresponding to their application in India. She has been working in the field of access to medicines, patents and IP for more than a decade.
LexBlog IP
NOVEMBER 22, 2021
The BPCIA also introduced a new scheme to resolve patent disputes involving biosimilar products known as the “patent dance.” ” Since the enactment of the BPCIA, the FDA has approved nearly 30 biosimilar products, and, as the market has grown, litigation activity concerning biosimilars has increased rapidly.
The IP Law Blog
JULY 15, 2021
CLS Bank Int’l , which involve the limits on patent eligibility under 35 U.S.C. § For example, in Alice, the court stated “[t]he ‘abstract ideas’ category embodies the longstanding rule that an idea of itself is not patentable.” Patent attorneys and inventors are often left to guess whether a particular invention is patent-eligible.
Expert insights. Personalized for you.
98 
Let's personalize your content